ORTX — Orchard Therapeutics Share News
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
Brief: European Medicines Agency Grants Orchard Therapeutics Accelerated Assessment Of OTL-200 For Patients With Metachromatic Leukodystrophy
Brief: Orchard Therapeutics Reports Third Quarter Results
Brief: Orchard Therapeutics To Present New Registrational Data Of Investigational Gene Therapies
Brief: Orchard Therapeutics PLC Files For Potential Mixed Shelf Offering
Brief: Orchard Therapeutics Announces Departure Of Chief Commercial Officer
Brief: Orchard Therapeutics Announces Encouraging Update From Proof-Of-Concept Study Of OTL-203 For The Treatment Of MPS-I
Brief: Orchard Therapeutics Presents Data Demonstrating Sustained Clinical Benefit Of OTL-200 For Treatment Of Metachromatic Leukodystrophy
Brief: Orchard Therapeutics Further Strengthens Board Of Directors With Appointment Of John Curnutte
Brief: Orchard Therapeutics To Present Data From Neurometabolic Portfolio
Brief: Orchard Therapeutics QTRLY Loss Per Share $0.56
Brief: Orchard Announces FDA Regenerative Medicine Advanced Therapy Designation Granted For OTL-103 For Treatment Of Wiskott-Aldrich Syndrome
Bluebird prices gene therapy at 1.575 mln euros over five years
U.S. STOCKS ON THE MOVE-AMD, Dupont, Ciena, At Home Group
U.S. STOCKS ON THE MOVE-At Home Group, Tesla, ContraVir, Cloudera, La Jolla
U.S. STOCKS ON THE MOVE-Cloudera, At Home Group, Tesla, Ciena, Stitch Fix
Gene therapy co Orchard Therapeutics slides on deep-discounted stock deal
U.S. STOCKS ON THE MOVE-Cruise stocks, bank stocks, chipmakers
Gene therapy firm Orchard Therapeutics sags ahead of stock offering
Brief: Orchard Therapeutics Announces Launch Of Proposed Public Offering Of 9 Million ADSS Representing 9 Million Ordinary Shares